Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Obesity

TrumpRx News: Why Donald Trump Struck a Deal With Novo Nordisk's Weight Loss Drugs — And What It Says About America's Obesity Problem

Certain GLP-1 weight loss medications will be available for as little as $149 per month, a sharp drop from the current average retail price of $1,000–$1,350.

International Business Times UK

Childhood obesity reaching ‘alarmingly high’ levels in Europe, WHO report warns

Child obesity rates have stabilised in some countries in recent years – but global health officials said they were still too high.

Euronews

Eli Lilly Crushed Novo In Obesity Drug Battle—Trump Now Forces Price Cuts

President Donald Trump unveiled a major pricing and coverage deal with drug giants Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) on Thursday, pledging to make blockbuster weight-loss drugs like Zepbound and Wegovy significantly cheaper and accessible for millions of Americans.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly, Novo Nordisk Make Weight-Loss Drugs More Affordable Via Medicare, Medicaid, TrumpRx

President Donald Trump on Thursday announced agreements with Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) to significantly reduce prices for their GLP-1-based obesity and diabetes drugs.

Benzinga

Trump announces plans to slim down cost of popular weight-loss drugs to $149 a month

Novo Nordisk and Eli Lilly become latest drug companies to bend knee to Trump’s ‘most-favored nation’ pricing plan

The Independent UK

Trump unveils deal to expand coverage and lower costs on obesity drugs

President Donald Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices for their popular obesity treatments Zepbound and Wegovy

The Independent UK

Higher-Dose Of Wegovy Demonstrates Weight Loss And Cardiovascular Benefits

At the ObesityWeek, Novo Nordisk A/S (NYSE:NVO) presented new findings from the STEP UP phase 3b trial.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

This is the exercise you need to combat obesity and diabetes, new study says

It’s estimated that more than 5.8 million people in the UK are living with diabetes, which is an all-time high, according to Diabetes UK

The Independent UK

Novo Nordisk Q3 2025 Earnings Call Transcript

Novo Nordisk A/S (NASDAQ:NVO) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below. NVO is having a challenging session. See if it is worth your attention here. This transcript is brought to you by Benzinga APIs. For real-time access to our entire…

Benzinga

Novo Nordisk cuts sales and profits guidance amid obesity drug competition

The boss of the Wegovy firm linked its reduced guidance to the market for weight-loss treatments being ‘more competitive than ever’.

Evening Standard

Pfizer, Novo Nordisk Locked in High-Stakes Fight Over Obesity Drug Innovator Metsera

Pfizer and Novo Nordisk are in a heated battle to acquire obesity drug developer Metsera, driving legal and market tension.

International Business Times

Ozempic Maker Novo Nordisk Trims Growth Outlook For Obesity Drugs

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported third-quarter 2025 sales of roughly $11.75 billion (74.98 billion Danish kroner), slightly below the consensus of $11.88 billion.

Benzinga

New food warnings could save thousands of peoples’ lives, experts say

Many countries have brought in a mandatory nutritional warning label law

The Independent UK

More than 100,000 obesity deaths ‘could be prevented with new food warnings’

Mandatory nutrient warning labels could deliver substantial health benefits for the population, experts said.

Evening Standard

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Trump team is negotiating with weight-loss drug makers to lower prices to $149 a month: report

Obesity drugs have become an increasingly popular method of weight loss but most are not covered by insurance for that purpose

Benzinga

Eli Lilly, Novo Nordisk Stocks Rise on Reported $149 Obesity Drug Deal with White House

Eli Lilly and Company (NYSE:LLY) shares are in the spotlight following reports indicating the company is close to finalizing a White House agreement to provide its lowest-dose obesity medications at $149 per month, which could open the door to Medicare coverage and broader reimbursement options.

Evening Standard

Child obesity crisis: London has worst record in weight surge for primary school youngsters, report reveals

More than a fifth of Year Six pupils in the capital are obese, according to new study

Evening Standard

Obesity levels among Reception and Year 6 children in England, by local area

The figures have been published as part of the Government’s National Child Measurement Programme.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Mapped: The areas where almost one in three children are obese

The figures were called ‘extremely concerning’ by the NHS national clinical director for children and young people

International Business Times

Pfizer Sues Rivals Metsera, Novo Nordisk Over Alleged Interference in Merger Talks

Pfizer sues Metsera and Novo Nordisk to block a rival bid in a high-stakes obesity drug merger.

Benzinga

Eli Lilly Seen In 'Pole Position' For Growth, Analysts Say

Eli Lilly and Co. (NYSE:LLY) reported better-than-expected third-quarter earnings on Thursday and boosted its annual forecast, sending the stock higher.

Benzinga

Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain

Healthcare ETFs are quietly feasting on the gains from Wall Street’s latest obsession – the $150 billion obesity-drug boom. As Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), and Pfizer Inc (NYSE:PFE) jostle for dominance in the fast-growing GLP-1 market, investors pile into ETFs that offer diversified and far…

The Independent UK

Obesity, diabetes treatments fuel Eli Lilly growth and spark bidding war

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a bidding war over the drugmaker Metsera

The Guardian - UK

Novo Nordisk bids $9bn for obesity drug maker Metsera in challenge to Pfizer

US biotech viewed as lucrative target partly because of its promising pipeline of weight-loss drugs

The Independent UK

Scientists discover five new genes which increase obesity risk

Scientists have identified 13 genes that could increase a person’s risk of developing obesity

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.